Sutro Biopharma (STRO) Set to Post Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Sutro Biopharma to announce earnings of ($1.6407) per share and revenue of $14.11 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Sutro Biopharma (NASDAQ:STRO) last announced its earnings results on Wednesday, August 12th. The company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($2.19) by ($0.14). The firm had revenue of $9.84 million during the quarter, compared to analyst estimates of $11.96 million. On average, analysts expect Sutro Biopharma to post ($8.41) EPS for the current fiscal year and ($6.95) EPS for the next fiscal year.

Sutro Biopharma Trading Up 0.1%

Shares of STRO opened at $9.11 on Tuesday. The business’s 50-day moving average price is $15.15 and its 200 day moving average price is $22.77. The stock has a market capitalization of $151.04 million, a P/E ratio of -0.76 and a beta of 1.49. Sutro Biopharma has a 1-year low of $7.15 and a 1-year high of $43.85.

Analyst Ratings Changes

Several research analysts have commented on STRO shares. Wells Fargo & Company assumed coverage on shares of Sutro Biopharma in a report on Wednesday, September 30th. They issued an “overweight” rating and a $49.00 target price for the company. Citizens Jmp cut their price target on shares of Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating on the stock in a report on Thursday, August 13th. Weiss Ratings downgraded shares of Sutro Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 19th. Stifel Nicolaus set a $48.00 price objective on shares of Sutro Biopharma and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Citigroup reiterated a “market outperform” rating on shares of Sutro Biopharma in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $49.50.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro’s research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.